Widening of the Excitable Gap During Pharmacological Cardioversion of Atrial Fibrillation in the Goat
Effects of Cibenzoline, Hydroquinidine, Flecainide, and d-Sotalol

Maurits C.E.F. Wijffels, MD, PhD; Rick Dorland, BSc; Frans Mast, PhD; Maurits A. Allessie, MD, PhD

Background—Previous studies suggest that the antifibrillatory action of class I and III drugs is due to prolongation of the atrial wavelength. The aim of the present study was to directly evaluate the electrophysiological action of antifibrillatory drugs in a goat model of chronic atrial fibrillation (AF).

Methods and Results—Six goats were instrumented with multiple atrial electrodes, and sustained AF was induced by electrical remodeling. During sustained AF, the effects of intravenous infusion of cibenzoline, hydroquinidine, flecainide, and d-sotalol on AF cycle length (AFCL), refractory period (RP_AF), conduction velocity (CV_AF), pathlength (PL_AF), wavelength (WL_AF), temporal (AFCL – RP_AF), and spatial (PL_AF – WL_AF) excitable gap were studied. The RP_AF was measured by determining the earliest moment at which single stimuli could capture the fibrillating atria. CV_AF was measured during regional entrainment of AF. Contrary to our expectation, cardioversion of AF could not be attributed to prolongation of WL_AF. Hydroquinidine and d-sotalol did not affect WL_AF significantly, whereas cibenzoline and flecainide even shortened WL_AF by 18% and 36%, respectively. PL_AF was increased by hydroquinidine and d-sotalol by 30%, whereas cibenzoline and flecainide did not prolong PL_AF. The only parameter that correlated consistently with cardioversion of AF was a widening of the temporal excitable gap (cibenzoline 176%, hydroquinidine 105%, flecainide 86%, d-sotalol 88%).

Conclusions—Pharmacological cardioversion of AF cannot be explained by prolongation of WL_AF. An alternative explanation for the antifibrillatory effect of class I and III drugs may be a widening of the temporal excitable gap. (Circulation. 2000;102:260-267.)

Key Words: fibrillation ■ drugs ■ conduction ■ waves

Mapping studies have shown that during atrial fibrillation (AF), multiple wavelets are propagating through the atria.1–4 Class I and III drugs are effective in cardioverting AF.5,6 Some studies have suggested that this antifibrillatory action is based on a prolongation of the atrial wavelength.7–10 When the wavelength during AF gets longer, the average number of multiple wavelets decreases, and the statistical chance that AF will terminate increases. In our goat model of chronic AF, a marked shortening of the atrial refractory period occurred during the first days of AF (AF-induced electrical remodeling).11 The resulting shortening of atrial wavelength and increase in the number of fibrillation waves are thought to play an important role in the development of sustained AF in this model.11 In a recent study, we compared the antifibrillatory efficacy of several class I and class III drugs in the goat.12 Surprisingly, although all drugs were highly effective in cardioverting AF, the atrial wavelength measured immediately after cardioversion was not prolonged. Accordingly, the vulnerability of the atria after cardioversion was still very high, and AF could easily be reinduced by single premature stimuli. This discrepancy between the high efficacy of these drugs in cardioverting AF and their inefficacy in preventing recurrences cannot be easily understood on the basis of our present knowledge of the action of these drugs.

In the present study, we used a new technique to measure the atrial refractory period during AF. In this way, the effects of class I and III drugs on the atrial refractory period, wavelength, and excitable gap could be directly evaluated during AF. Contrary to our expectation, the action of antifibrillatory drugs could not be attributed to a prolongation of the atrial wavelength. Instead, pharmacological cardioversion of AF was consistently associated with a progressive widening of the temporal excitable gap during AF.

Methods
Six female goats (weight 55 ± 7 kg) were used for this study. During general anesthesia and open-chest surgery,11,12 83 electrodes were sutured onto the surface of both atria (23 on Bachmann’s bundle, 30 on the right atrium, and 30 on the left atrium). The interelectrode
distance on Bachmann’s bundle was 4 to 10 mm and on the atrial free wall, 4 to 5 mm (Figure 1). Four electrodes were sutured onto the left ventricle. Three subcutaneous silver plates were used as indifferent electrode and to record a precordial ECG. After recovery from surgery, the goats were connected to an external fibrillation pacemaker to induce sustained AF.11 Pharmacological cardioversion was performed after AF had become sustained (lasting >24 hours). During cardioversion, all electrograms were recorded simultaneously (gain 200 to 400, bandwidth 1 to 500 Hz, sampling rate 1 kHz). The AF cycle length (AFCL) was measured by an automatic algorithm detecting the moments of local activation during 300 consecutive intervals. Refractory period (RP AF) and conduction velocity (CV AF) during AF permits regional entrainment of the atria.13 The RP AF (difference between pathlength and wavelength) can be estimated. and atrial refractoriness during AF), and the spatial excitable gap (PLAF) the average pathlength of the multiple wavelets can be calculated were measured every 5 to 10 minutes during AF. From these values, the window of unstable entrainment (defined as capture by 5 consecutive stimuli) was determined in a similar fashion.

During control, the AFCL, RP AF, and CV AF were measured ±6 times. Then drug infusion was started, and AFCL, RP AF, and CV AF were measured every 5 to 10 minutes. Cibenzoline and flecainide were infused at a speed of 0.1 mg · kg⁻¹ · min⁻¹; hydroquinidine and d-sotalol at 0.2 mg · kg⁻¹ · min⁻¹. Infusion was terminated when sinus rhythm was restored or adverse drug effects occurred (QRS prolongation of >70% or ventricular tachyarrhythmias). The different drugs were applied in an arbitrary but nonrandom order. Sufficient time was allowed between experiments for complete washout of the drugs. Conversion to atrial flutter was not observed in the present series, and in all cases, during pharmacological cardioversion, atrial cycle length, atrial electrogram morphology, and ventricular rate remained irregular. Data are given as mean±SD. For statistical analysis, a paired Student’s t test was used. A value of P<0.05 was considered statistically significant.

Results

Cibenzoline

In Figure 4, an example is given of the measurement of the RP AF during infusion of cibenzoline. Cibenzoline caused a clear dose-dependent prolongation of the median AFCL from 98 to 169 ms. During control, a stimulus with a coupling...
interval of 76 ms captured the atrium. Cibenzoline clearly prolonged the RP_{AF}, the shortest coupling interval now capturing the atrium being 100 ms. The captured response showed a negative low-amplitude waveform, whereas the AFCL during capture was shorter than expected and was followed by a long AFCL. In Figure 5, the electrophysiological effects of cibenzoline during pharmacological cardioversion are plotted. AF was cardioverted after 43 minutes of infusion, when the median AFCL had been prolonged from 96 to 198 ms. Because the RP_{AF} was prolonged only from 74 to 115 ms, the temporal excitable gap (excitable period, EP_{AF}) widened from 22 to 83 ms. As expected, CV_{AF} progressively decreased from 63 to 39 cm/s. Because the prolongation of RP_{AF} was counterbalanced by a slowing in CV_{AF}, the WL_{AF} did not change significantly (4.6 versus 4.4 cm). However, because the AFCL prolonged more than the CV_{AF} decreased, the estimated pathlength of the fibrillation waves increased from 6.1 to 7.6 cm. Thus, the spatial excitable gap (PL_{AF}−WL_{AF}) also prolonged from 1.5 to 3.2 cm. In Table 1, the effects of cibenzoline are given for all goats. At the highest concentration, cibenzoline increased AFCL by 79%, RP_{AF} by 37%, and EP_{AF} by 191% (all P<0.01). The windows of stable and unstable entrainment widened from 12±4 to 37±6 ms and from 31±5 to 63±4 ms, respectively (both P<0.001). CV_{AF} decreased by 42% (P<0.01). Although the

![Figure 3](http://circ.ahajournals.org/)

**Figure 3.** Measurement of intra-atrial conduction velocity during stable entrainment of AF. During AF, atrium was paced with an interval equal to median AFCL (106 ms) at border of mapping electrode. During stable capture, activation maps were made (left) and local conduction velocities were calculated within each triangle of electrodes (right). Two unipolar electrograms at top were recorded at 5 and 22 mm from pacing site (circled electrodes on isochrone map).

![Figure 4](http://circ.ahajournals.org/)

**Figure 4.** Measurement of RP_{AF}. Unipolar electrogram was recorded 4 mm from pacing site. Shortest coupling interval capturing fibrillating atrium was 76 ms during control and 100 ms after cibenzoline infusion.

![Figure 5](http://circ.ahajournals.org/)

**Figure 5.** Example of effects of cibenzoline on AF. Top, Median AFCL and P_5 and P_95 values (bars) are plotted together with RP_{AF}. Bottom, Effects on CV_{AF} and calculated PL_{AF} and WL_{AF} during AF are plotted. After 43 minutes, AF was cardioverted by cibenzoline.
Hydroquinidine
In Figure 6, the effects of hydroquinidine are given. Before drug infusion, the median AFCL was 99 ms and RP_{AF}, 72 ms. Hydroquinidine progressively increased AFCL until AF cardioverted at a cycle length of 148 ms. Because the RP_{AF} remained as short as 87 ms, the EP_{AF} increased from 27 to 61 ms. CV_{AF} decreased only slightly, from 87 to 76 cm/s. Therefore, the PL_{AF} increased from 8.7 to 11.2 cm, whereas the WL_{AF} of 6.2 cm was not affected. In all 5 goats (Table 1), the prolongation of AFCL from 96±17 to 148±11 ms (57%; P<0.001) was associated with an increase in RP_{AF} from 67±15 to only 79±15 ms (16%; P<0.05). The EP_{AF} thus widened from 29±10 to 69±16 ms (157%; P<0.01). The window of entrainment increased from 12±11 to 34±15 ms (stable capture; P<0.001) and from 32±7 to 70±12 ms (unstable capture; P<0.001). The wavelength was not changed (4.8±1.8 versus 4.9±1.7 cm).

Flecainide
In Figure 7 and Table 1, the effects of flecainide on AF are given. Flecainide prolonged AFCL by 48%, whereas RP_{AF} did not change significantly. Thus, the excitable period increased from 23±5 to 63±9 ms (189%; P<0.01). The windows of stable and unstable entrainment increased from 9±5 to 30±13 ms and from 27±8 to 55±13 ms, respectively (P<0.05). Because RP_{AF} did not change and CV_{AF} was depressed by 44%, flecainide shortened the atrial wavelength during AF by 41% (P<0.05).

d-Sotalol
In Figure 8 and Table 1, the effects of d-sotalol are given. Compared with the class I drugs, d-sotalol prolonged AFCL less markedly (24%; P<0.001). As expected, CV_{AF} was not affected by d-sotalol. In addition, RP_{AF} was not prolonged (71±18 versus 70±20 ms), and WL_{AF} was unaltered (4.5±1.9 versus 4.8±1.9 cm; P=0.17). The EP_{AF} prolonged from 23±3 to 47±11 ms (102%; P<0.01), and the stable and unstable windows of entrainment widened from 7±10 to

### Table 1. Effects of 4 Drugs for All Goats

<table>
<thead>
<tr>
<th>Drug</th>
<th>AFCL, ms</th>
<th>RP_{AF}, ms</th>
<th>EP_{AF}, ms</th>
<th>PL_{AF}, cm</th>
<th>WL_{AF}, cm</th>
<th>EG_{AF}, cm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cibenzoline</td>
<td>96±4</td>
<td>69±8</td>
<td>27±5</td>
<td>12±4 (83–95)</td>
<td>31±5 (75–106)</td>
<td>71±17 (6.8±1.5)</td>
</tr>
<tr>
<td>Cibenzoline_{25%}</td>
<td>120±7</td>
<td>80±11</td>
<td>40±9</td>
<td>...</td>
<td>...</td>
<td>48±11 (5.8±1.4)</td>
</tr>
<tr>
<td>Cibenzoline_{max}</td>
<td>171±8</td>
<td>95±15</td>
<td>76±10</td>
<td>37±6</td>
<td>63±4</td>
<td>42±15 (7.2±2.7)</td>
</tr>
<tr>
<td>Hydroquinidine</td>
<td>96±17</td>
<td>65±19</td>
<td>29±10</td>
<td>12±11 (91–111)</td>
<td>32±7 (78–110)</td>
<td>69±21 (6.8±2.3)</td>
</tr>
<tr>
<td>Hydroquinidine_{25}</td>
<td>125±18</td>
<td>74±20</td>
<td>51±11</td>
<td>...</td>
<td>...</td>
<td>59±19 (7.5±2.6)</td>
</tr>
<tr>
<td>Hydroquinidine_{max}</td>
<td>148±11</td>
<td>79±19</td>
<td>69±16</td>
<td>34±15</td>
<td>70±12</td>
<td>61±15 (9.1±2.5)</td>
</tr>
<tr>
<td>Flecainide</td>
<td>91±8</td>
<td>68±7</td>
<td>23±5</td>
<td>9±5 (85–96)</td>
<td>27±8 (75–102)</td>
<td>58±9 (5.3±0.9)</td>
</tr>
<tr>
<td>Flecainide_{25%}</td>
<td>110±9</td>
<td>72±10</td>
<td>38±7</td>
<td>...</td>
<td>...</td>
<td>45±11 (5.0±1.3)</td>
</tr>
<tr>
<td>Flecainide_{max}</td>
<td>134±8</td>
<td>71±12</td>
<td>63±9</td>
<td>30±13</td>
<td>55±13</td>
<td>33±13 (4.3±1.7)</td>
</tr>
<tr>
<td>d-Sotalol</td>
<td>94±17</td>
<td>71±18</td>
<td>23±3</td>
<td>7±10 (99–116)</td>
<td>27±9 (78–105)</td>
<td>63±24 (5.9±2.3)</td>
</tr>
<tr>
<td>d-Sotalol_{25%}</td>
<td>112±20</td>
<td>71±18</td>
<td>44±7</td>
<td>...</td>
<td>...</td>
<td>65±24 (7.3±2.6)</td>
</tr>
<tr>
<td>d-Sotalol_{max}</td>
<td>116±19</td>
<td>70±20</td>
<td>47±11</td>
<td>20±14</td>
<td>54±6</td>
<td>68±21 (7.9±2.5)</td>
</tr>
</tbody>
</table>

Numbers represent mean±SD. Values were obtained during control, at AFCL prolongation of 20% or 25%, and at maximal AFCL prolongation. *P<0.05; †P<0.01; ‡P<0.001.
20 ± 14 ms (P < 0.05) and from 27 ± 9 to 54 ± 6 ms, respectively (P < 0.01). The estimated PL AF prolonged from 5.9 ± 2.3 to 7.9 ± 2.5 cm (39%; P < 0.01), whereas the EG AF widened from 1.4 ± 0.5 to 3.1 ± 0.9 cm (126%; P < 0.01).

Electrophysiological Determinants of Pharmacological Cardioversion

The electrophysiological effects of cibenzoline, hydroquinidine, flecainide, and d-sotalol just before cardioversion are listed in Table 2. Both hydroquinidine and d-sotalol successfully restored sinus rhythm in all 5 goats. Cibenzoline and flecainide were less effective and restored sinus rhythm in 80% and 40%, respectively. Of the different class I drugs, cibenzoline increased AFCL more (69%) than hydroquinidine (37%) and flecainide (30%), whereas the class III drug d-sotalol increased AFCL by only 21%. In all cases, the prolongation in AFCL outweighed the increase in RPAF. As a result, the excitable period before cardioversion was markedly prolonged by all drugs. Class IC drugs (cibenzoline and flecainide) depressed CVAF most. In contrast, cardioversion of AF by d-sotalol occurred without any significant slowing of conduction. The WL AF was not altered by hydroquinidine and d-sotalol. Restoration of sinus rhythm by cibenzoline and flecainide was associated with a shortening of WL AF of 18% and 36%, respectively. The PL AF was either shortened or lengthened during the last minutes before cardioversion of AF. Because of its marked depression of CVAF, flecainide shortened the average pathlength of the fibrillation waves by 22%, whereas cardioversion by hydroquinidine and d-sotalol was associated with an increase in path length of 30%. Cibenzoline had no effect on PL AF. The spatial excitable gap before cardioversion was prolonged by 3 of the 4 drugs (67% to 102%). In contrast, cardioversion of AF by flecainide was not associated with widening of the EG AF.
Widening of the Temporal Excitable Gap During AF

Measurement of the RP_{AF} by single premature stimuli revealed that all 4 drugs widened the EP_{AF}. Figure 9 shows that this is not an artifact and may have functional implications. The unipolar atrial electrogram during AF was recorded after 40 minutes of hydroquinidine infusion. As a result, the AFCL was prolonged from 70 to 135 ms. Despite this slowing in fibrillation rate, the characteristics of AF were still preserved, and variations in electrogram morphology and cycle length were associated with a totally irregular ventricular rhythm. In the middle of the tracing, a single early stimulus of 48 ms was delivered, which resulted in a sudden marked acceleration of AF. The interval plot below the tracing shows that the AFCL shortened from 135 to <70 ms. Acceleration of AF was also observed during administration of the other drugs, confirming that the drug-induced slowing of AF was associated with a widening of the functional excitability period.

In Figure 10, the effects of all drugs are compared qualitatively. The prolongation of AFCL was most pronounced for cibenzoline and hydroquinidine, less for flecainide, and relatively small for d-sotalol. In neither case could the prolongation in AFCL be satisfactorily explained by an increase in the RP_{AF}. In some experiments, prolongation of AFCL and cardioversion of AF were even associated with a shortening of the refractory period. As a result, all drugs widened the EP_{AF}. Cibenzoline and flecainide (class IC) slowed CV_{AF} markedly, whereas hydroquinidine depressed conduction only slightly. The slight increase in CV_{AF} by d-sotalol can be explained by a slowing in atrial rate and the associated improved recovery of excitability.

Discussion

Antifibrillatory Drugs Do Not Prolong the Wavelength During AF

In chronically instrumented dogs, it was found that the atrial wavelength played a crucial role for the induction of atrial arrhythmias. Kirchhof et al. explained the antifibrillatory action of ORG7797 by a wavelength prolongation at high pacing rates. In a canine model of vagally mediated AF, Wang et al. found that the degree of AFCL prolongation by various drugs was similar to the increase in atrial refractory period during rapid pacing. Because mapping of AF showed a reduction in the number of wavelets, they concluded that the antifibrillatory action was based on prolongation of the atrial wavelength. Our data are in clear contrast to these results. In a previous study, we reported that after pharmacological cardioversion, the atrial wavelength was short (7 to 9 cm) and AF was readily reinduced by a single premature stimulus. Measurements of the refractory period during AF now directly demonstrated that cardioversion by class I and III drugs cannot be attributed to prolongation of the wavelength. Although theoretically, prolongation of the atrial wavelength can certainly lead to termination of AF, actually the antifibrillatory action was based on another mechanism. Because it is unknown whether the present findings are species-dependent or due to electrical remodeling, it would be worthwhile to measure the excitable gap during pharmacological cardioversion of human AF.

Antifibrillatory Drugs Prolong the Excitable Period During AF

During AF, functional and anatomic reentry occurs, leaving a short temporal excitable gap between the fibrillation waves. Below, we propose a number of mechanisms by which the EP may be prolonged by class I drugs. In an anatomic circuit, the EP is the difference between the conduction time around the anatomic obstacle and the refractory period. Drugs that slow conduction thus widen the EP by prolonging the revolution time. During functional reentry, the impulse is circulating around a line of functional conduction block, often making a sharp U-turn at the pivot point. At these sites, because of the high wavefront curvature, a current-to-load mismatch exists that leads to conduction delay at the pivot point. In a canine model of atrial flutter, Ortiz et al. showed that moricizine increased the flutter cycle length by 23% to 44%, whereas the refractory period was only slightly prolonged (<7%). Termination of flutter was not due to wavelength prolongation but rather to preferential conduction slowing at the pivot point. The observed widening of the excitable period during AF by class I drugs thus may be due to aggravation of the wavefront-curvature effect of the turning fibrillation waves. During AF, random reentry also occurs when a wavelet reenters an area previously activated by another wavelet. In this case, the excitable period is determined by the time the cells have to wait until they are excited by another wavelet. Drugs that decrease the number of wavelets will widen the EP_{AF} because with a lower number of wavelets available, the average waiting time for reexcitation will become longer. If the size of functional circuits increases, anatomic obstacles may become incorporated in the circuit. Such a shift from functional to anatomic reentrant pathways may be an additional reason for widening of the EP_{AF} by antifibrillatory drugs.
Is Widening of the Excitable Gap Antifibrillatory? Although cibenzoline, hydroquinidine, flecainide, and d-sotalol all were effective in cardioverting chronic AF, they exerted different effects on \( R_{PAF} \), \( CV_{AF} \), \( PL_{AF} \), and \( WL_{AF} \). The only action these 4 drugs had in common was a widening of the temporal excitable gap during AF. Although of course this does not prove anything, it raises the question of whether the antifibrillatory drug action is caused by a widening of the excitable gap. According to Moe’s multiple-wavelet hypothesis, the stability of AF is determined by the average number of wavelets.\(^1\) Mapping studies have indicated that during AF, the number of wavelets varies considerably as a result of variation in rate of wave formation and extinction.\(^2\)–\(^4\) Because the number of wavelets varies considerably as a result of atrial abnormalities due to dilatation, ischemia, or old age,\(^22\)–\(^25\) the number of animals used in this study was rather small. However, because the drug effects were quite large and consistent, most of the observed changes were statistically significant. We cannot exclude the possibility that other parameters will also show significant changes if studied in a larger series of animals. The mechanisms underlying the observed widening of the excitable gap during AF were not directly evaluated. Therefore, although we consider preferential slowing at pivot points an attractive explanation, other mechanisms, such as slowing of conduction in anatomic circuits, prolongation of the “waiting time” of random reentry, and even depression of automatic foci, cannot be excluded. The antifibrillatory mechanism of d-sotalol remains obscure, because during AF in remodeled atria, d-sotalol exerted no class III effect. Whether the observed increase in excitable gap was due to blockade of sodium channels by high concentrations of d-sotalol remains unknown.\(^26\) Finally, drug effects on \( CV_{AF} \) were studied during entrainment of AF. Although this method has the advantage that beat-to-beat changes in direction and fragmentation of the fibrillation waves do not occur, it may underestimate the actual effects of class I drugs on conduction during AF when the safety factor of the fibrillation waves is lowered by fragmentation.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Cardiover-</th>
<th>AFCL, ms</th>
<th>( R_{PAF} ), ms</th>
<th>( CV_{AF} ), cm/s</th>
<th>( WL_{AF} ), cm</th>
<th>( PL_{AF} ), cm</th>
<th>( EP_{AF} ), ms</th>
<th>( PL_{AF} ), cm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cibenzoline</td>
<td>80</td>
<td>98±2</td>
<td>165±18</td>
<td>72±7</td>
<td>97±17</td>
<td>26±6</td>
<td>68±3</td>
<td>65±13</td>
</tr>
<tr>
<td>Hydroquinidine</td>
<td>100</td>
<td>96±16</td>
<td>130±17</td>
<td>67±15</td>
<td>74±19</td>
<td>29±10</td>
<td>56±15</td>
<td>69±21</td>
</tr>
<tr>
<td>Flecainide</td>
<td>40</td>
<td>96±8</td>
<td>125±2</td>
<td>68±10</td>
<td>71±17</td>
<td>28±2</td>
<td>54±16</td>
<td>50±6</td>
</tr>
<tr>
<td>d-Sotalol</td>
<td>100</td>
<td>94±17</td>
<td>114±20</td>
<td>71±18</td>
<td>70±20</td>
<td>23±3</td>
<td>43±10</td>
<td>63±24</td>
</tr>
<tr>
<td>Mean±SD</td>
<td>80</td>
<td>96±1</td>
<td>134±19</td>
<td>70±2</td>
<td>78±11</td>
<td>27±2</td>
<td>55±9</td>
<td>62±7</td>
</tr>
</tbody>
</table>

\( *P<0.05; † P<0.01; NS, not significant, control vs values before sinus rhythm. \)

\( CAF \) indicates chronic AF. Numbers represent mean±SD of the mean and the mean percentage change in the given parameters.

In summary, we propose the following hypothesis for termination of AF by class I drugs: (1) The lowering of the availability of rapid sodium channels causes preferential depression of conduction of wavelets with a high curvature.\(^15\) (2) This results in preferential conduction delay at the pivot points of turning wavelets. (3) The delay at the pivot points causes an increase in the average AF cycle length and a widening of the temporal excitable gap. (4) Because of a better recovery of excitability, the balance between fusion and fragmentation of wavelets will change in favor of fusion. (5) The resulting reduction in the average number of fibrillation waves increases the statistical chance of termination of AF.

**Limitations**

An important limitation of the present study is that apart from the presence of electrical remodeling, the atria were normal. Although clinically, electrical atrial remodeling may also play a role,\(^21\) in humans the arrhythmia is often associated with atrial abnormalities due to dilatation, ischemia, or old age.\(^22\)–\(^25\) The number of animals used in this study was rather small. However, because the drug effects were quite large and consistent, most of the observed changes were statistically significant. We cannot exclude the possibility that other parameters will also show significant changes if studied in a larger series of animals. The mechanisms underlying the observed widening of the excitable gap during AF were not directly evaluated. Therefore, although we consider preferential slowing at pivot points an attractive explanation, other mechanisms, such as slowing of conduction in anatomic circuits, prolongation of the “waiting time” of random reentry, and even depression of automatic foci, cannot be excluded. The antifibrillatory mechanism of d-sotalol remains obscure, because during AF in remodeled atria, d-sotalol exerted no class III effect. Whether the observed increase in excitable gap was due to blockade of sodium channels by high concentrations of d-sotalol remains unknown.\(^26\) Finally, drug effects on \( CV_{AF} \) were studied during entrainment of AF. Although this method has the advantage that beat-to-beat changes in direction and fragmentation of the fibrillation waves do not occur, it may underestimate the actual effects of class I drugs on conduction during AF when the safety factor of the fibrillation waves is lowered by fragmentation.
### Acknowledgment

This study was supported by the Netherlands Organization for Scientific Research.

### References


Widening of the Excitable Gap During Pharmacological Cardioversion of Atrial Fibrillation in the Goat: Effects of Cibenzoline, Hydroquinidine, Flecainide, and d-Sotalol
Maurits C. E. F. Wijffels, Rick Dorland, Frans Mast and Maurits A. Allessie

Circulation. 2000;102:260-267
doi: 10.1161/01.CIR.102.2.260

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2000 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/102/2/260

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/